Prot #UPCC02614/565193: NU UP16M02: The BAMM Trial: BRAF, Autophagy and MEK inhibition in Metastatic Melanoma: A Phase 1/2 Open Label Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Patients with Advanced BRAF Mutant Melanoma
- Chandra, Sunandana (PD/PI)
Project: Research project